Next Article in Journal
Computational Analysis of the Interaction Energies between Amino Acid Residues of the Measles Virus Hemagglutinin and Its Receptors
Next Article in Special Issue
Encapsidated Host Factors in Alphavirus Particles Influence Midgut Infection of Aedes aegypti
Previous Article in Journal
Attenuated Phenotype and Immunogenic Characteristics of a Mutated Herpes Simplex Virus 1 Strain in the Rhesus Macaque
Previous Article in Special Issue
Mutation of CD2AP and SH3KBP1 Binding Motif in Alphavirus nsP3 Hypervariable Domain Results in Attenuated Virus
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Viruses 2018, 10(5), 235;

Current Strategies for Inhibition of Chikungunya Infection

School of Pharmaceutical Sciences, Siksha O Anusandhan Deemed to be University, Bhubaneswar 751029, India
Institute of Life Sciences, Bhubaneswar 751023, India
Authors to whom correspondence should be addressed.
Received: 16 March 2018 / Revised: 7 April 2018 / Accepted: 8 April 2018 / Published: 3 May 2018
(This article belongs to the Special Issue Advances in Alphavirus Research)
Full-Text   |   PDF [28369 KB, uploaded 3 May 2018]   |  


Increasing incidences of Chikungunya virus (CHIKV) infection and co-infections with Dengue/Zika virus have highlighted the urgency for CHIKV management. Failure in developing effective vaccines or specific antivirals has fuelled further research. This review discusses updated strategies of CHIKV inhibition and provides possible future directions. In addition, it analyzes advances in CHIKV lifecycle, drug-target development, and potential hits obtained by in silico and experimental methods. Molecules identified with anti-CHIKV properties using traditional/rational drug design and their potential to succeed in subsequent stages of drug development have also been discussed. Possibilities of repurposing existing drugs based on their in vitro findings have also been elucidated. Probable modes of interference of these compounds at various stages of infection, including entry and replication, have been highlighted. The use of host factors as targets to identify antivirals against CHIKV has been addressed. While most of the earlier antivirals were effective in the early phases of the CHIKV life cycle, this review is also focused on drug candidates that are effective at multiple stages of its life cycle. Since most of these antivirals require validation in preclinical and clinical models, the challenges regarding this have been discussed and will provide critical information for further research. View Full-Text
Keywords: alphavirus; antiviral; chikungunya; drug likeness; drug targets; pre-clinical validation alphavirus; antiviral; chikungunya; drug likeness; drug targets; pre-clinical validation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Subudhi, B.B.; Chattopadhyay, S.; Mishra, P.; Kumar, A. Current Strategies for Inhibition of Chikungunya Infection. Viruses 2018, 10, 235.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top